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Abstract 
By varying the molecular charge, shape and amphiphilicity of a series of conformationally 
distinct diarylureas it is possible to control the levels of phospholipid membrane lysis using 
membranes composed of bacterial lipid extracts. From the data obtained, it appears as though 
the lysis activity observed is not due to charge, conformation or amphiphilicity in isolation, 
but that surface aggregation, H-bonding and other factors may also play a part. The work 
provides evidence that this class of foldamer possesses potential for optimisation into new 
antibacterial agents. 
 
Introduction 
There can no longer be any doubt that new antibacterial agents are needed, drugs which not 
only have potent activity against resistant strains of bacteria, but which are less susceptible to 
developing resistance at a later date. The crisis associated with antimicrobial resistance has 
generated major world-wide opportunities for science and technology to lead the way, and 
one area that could deliver some of the answers is the field dedicated to foldamer research.1-5 
A foldamer can be defined as “a discrete oligomer that folds into a conformationally ordered 
state in solution”, and contemporary research has shown that a number of foldamer constructs 
(in particular, antimicrobial peptides (AMPs)) can interact with, and disrupt, bacterial cell 
membranes thus making these agents valid candidates for future therapeutics, particularly if 
selectivity over host cells can be achieved.6-14 
 
In light of this need, our research group has recently developed a range of AMP-influenced 
mimetics which are based on a foldamer scaffold, under the presumption that control over 
antimicrobial properties could be obtained by fine-tuning the molecules’ charge, 
amphiphilicity and conformation.8,10-13,15-19 Previous efforts have looked at the influence of 
foldamer length and conformation on membrane interaction,15-19 but as yet, the effects of 
charge and thereby amphiphilicity have not been studied against bacterial membranes by us. 
Herein, we outline recent efforts in this area and discuss the significance of these molecular 
properties on the ability of the compounds to lyse membranes composed of lipids extracted 
from Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli), with the aim of 
developing a new class of antibacterial agent. 
 
Results and Discussion 
It is well established that N-unsubstituted diarylureas exhibit a distinct difference in 
conformation when compared to their fully N-substituted counterpart, both in solution and the 
solid state (Figure 1). For instance, upon full methylation, N,N’-diphenylurea changes from 
the trans,trans-conformation to the cis,cis-conformation, as shown.20-23  
 
 
Figure 1: Conformational change induced in diphenylureas upon N-methylation. 
 
In such a case the conformation can be determined by either 1H NMR (solution state 
conformation), as evidenced by a diagnostic upfield shift in the aromatic signals, or by 
obtaining the X-ray crystal structures to determine the conformation in the solid state.24 
 
The consequence of achieving such conformational control by simple N-substitution has been 
studied in a number of applications, not least: for facilitating conformational communication 
via stereogenic axes;25 for controlling oligourea helicity;26,27 for designing promising 
anticancer and anti-bacterial agents;15-17,28 as a molecular splint;29 for carrying out a so-called 
‘impossible’ macrocyclisation;30 and for the development of fluorescent sensors.31 
 
Another way to potentially exploit this conformational switch is to prepare and evaluate 
compounds, which as a result, differ in their molecular dimensions and functionalities, such 
that activity can be studied and apportioned to the individual properties of interest in both the 
trans and cis forms, in this case their ability to lyse bacterial membranes; it is assumed that 
the pKa of the compounds being prepared, and thus their protonation state in the assay media, 
would be the same for both conformations. 
 
In order to be able to test each property individually (conformation, charge and thereby 
amphiphilicity) a series of compounds were designed and prepared which exist in two 
discrete and stable conformations depending upon their N-methylation status, as outlined in 
Scheme 1 and Figure 2.  
 
 
Scheme 1: Synthesis of the test compounds. 
 
 
Figure 2: Compounds synthesised to test the influence of conformation, charge and amphiphilicity on 
membrane lysis. The percentages in parentheses are the approximate calculated values for protonation of the 
amine or pyridine nitrogen at pH 7.4 using the Henderson–Hasselbalch equation (see Supporting Information). 
 
The compounds in Figure 2 were chosen to enable a direct comparison to be made between 
the level of membrane lysis achieved between compounds in the same conformation state, but 
differing protonation levels (series 1-3 and 4-7) vs. compounds in the same protonation state, 
but differing conformation (1 vs 4, 2 vs 5 and 3 vs 6). Compound 7 was a hybrid-type 
structure with both N-Me and N-H functionality and a protonation site. 
 
Table 1: Percentage release for compounds 1-7 against calcein-loaded lipid vesicles prepared from the total 
phospholipid content extracted from the membrane of S. aureus. The values shown are the average and standard 
deviations of five experiments. 
Concentration (μM) 1 2 3 4 5 6 7 
0 0 0 0 0 0 0 0 
93.73 7.18±0.49 4.58±0.27 6.91±0.06 2.59±1.03 4.45±0.05 4.45±2.49 39.98±0.18 
187.5 9.20±1.32 8.34±0.19 11.23±0.57 5.71±0.13 7.13±0.05 10.00±0.18 48.25±0.11 
375 13.84±0.16 10.09±0.25 17.81±0.50 12.79±0.28 12.02±0.65 11.80±0.37 49.58±0.32 
750 15.34±0.07 12.67±0.41 27.24±1.95 14.16±0.41 15.29±0.99 13.21±0.20 51.53±0.72 
1500 18.34±0.23 13.84±0.52 31.25±0.40 15.14±0.48 21.23±0.53 15.27±0.99 53.10±1.07 
3000 25.50±0.99 15.47±0.30 44.09±0.15 24.10±0.35 27.00±0.36 17.84±0.60 54.62±1.88 
 
Table 2: Percentage release for compounds 1-7 against calcein-loaded lipid vesicles prepared from the total 
phospholipid content extracted from the membrane of E. coli. The values shown are the average and standard 
deviations of five experiments. 
Concentration (μM) 1 2 3 4 5 6 7 
0 0 0 0 0 0 0 0 
93.73 3.17±0.26 0.15±0.79 1.10±2.23 0.82±0.62 2.30±0.31 8.45±1.23 24.05±0.16 
187.5 6.27±3.19 0.95±0.58 6.06±0.68 2.05±0.65 5.72±0.20 27.22±2.42 24.81±0.05 
375 6.47±1.46 1.24±0.69 9.17±2.04 4.25±1.35 6.75±0.40 29.32±0.17 26.28±0.62 
750 8.53±0.22 1.73±0.56 16.63±4.19 6.44±1.96 7.44±0.62 29.98±0.32 29.08±2.60 
1500 12.02±0.14 1.78±0.47 23.46±3.42 7.28±0.87 8.03±0.43 30.97±0.42 33.61±0.12 
3000 14.85±1.73 2.17±0.70 29.17±0.53 9.02±0.65 9.65±0.30 35.55±1.12 35.31±0.09 
 
Tables 1 and 2 show the concentration-dependent lysis of compounds 1-7 against membrane 
extracts from S. aureus and E.coli respectively, over a treatment period of 1h, in a calcein-
release assay. The relatively weak maximum levels of lysis obtained, even at the highest 
concentrations, suggests that the compound-membrane interactions are not optimised against 
the membranes being studied. These results were confirmed in minimum inhibitory 
concentration (MIC) studies against cultures of both bacterial strains (Table 3), whereby 
relatively high values were observed. However, it should be noted that these are small, 
individual monomer molecules interacting with relatively large phospholipid membranes 
which are usually disrupted by large aggregated oligomers. Herein attempts have been made 
to identify key features for membrane interaction and disruption which will be taken forward 
into larger oligomers in future work. 
 
Nonetheless, modest levels of membrane lysis are observed at the lowest concentration 
studied (Tables 1 and 2), where the highest levels are given by 7 (~40%) against S. aureus 
and 7 (~24%) against E. coli. Importantly, the variety of lysis levels obtained against both 
strains is indicative of some selectivity being observed with the different compounds, which 
differ in their charge, shape and amphiphilicity, against theses membranes, suggesting that 
once optimised, this class of molecule could be developed as pathogen-selective 
antimicrobial agents. 
 
Table 3: Minimum inhibitory concentration (MIC) studies against both S. aureus and E. coli cultures. 
Bacteria 1 2 3 4 5 6 7 
S. aureus 2.0 mM 2.5 mM 1.5 mM 2.5 mM 2.0 mM 2.5 mM 1.0 mM 
E. coli > 3.0 mM > 3.0 mM 2.0 mM > 3.0 mM > 3.0 mM 2.0 mM 2.0 mM 
 
Comparisons: Structure and lysis 
Against S. aureus the trans,trans-compounds 1, 2 and 3 are more membrane lytic than the 
cis,cis-isomers 4, 5 and 6 at almost all concentrations studied, with 3 being the most potent 
compound overall. Presumably, this is the case because this amine is the most ionised at the 
pH used (pH 7.4, Figure 2), but that conformation or H-bonding must play a role too, since 
these are the main structural differences between compounds 3 and the less active analogue, 
6. That said, compound 7, a cis,cis-diarylurea-NH-amide, which is less completely protonated 
at pH 7.4, is better still by several fold than all the trans,trans-compounds suggesting that 
more complicated factors are at play.  
 
Interestingly, in the context of pathogen-selectivity, against E. coli the pattern is different, 
with 1 being the best of the trans,trans-analogues (despite being neutral at pH 7.4), although 
the overall levels of lysis are slightly lower than the same compounds against S. aureus. 
Conversely, in all cases, the cis,cis-compounds (5 and 6) tend to be more active than the 
trans,trans-compounds (2 and 3), with compound 6 being the best diarylurea overall by 
several fold, and comparable to compound 7. 
 
From the data in Tables 1 and 2 it appears as though lysis does correlate with the pKa of the 
nitrogen which is protonated for compounds 1-6, such that the glycine derivatives 3 and 6 
(99.9% positively charged) are consistently the best lytic compounds against both membrane 
types. The membrane of S. aureus is mainly composed of the negatively charged 
dimyristoylphosphatidylglycerol (DMPG) lipid, whilst the membrane of E. coli is mainly the 
negatively charged DMPG and the zwitterionic (neutral) 
dimyristoylphosphatidylethanolamine (DMPE) lipid.32 As such, with the membrane’s overall 
negative charge, it is expected that the positively charged compounds 3 and 6 would be the 
best at interacting with the membranes and ultimately lysing them at a critical concentration 
(albeit relatively high with these low molecular weight, un-optimised compounds). In 
addition, hydrophobic features to penetrate the lipid layer of the membrane are important 
confirming that amphiphilic molecules as a whole are required.8 
 
Interestingly, compound 4 is poor against both strains of bacteria, as would be expected for a 
neutral, weakly amphiphilic compound with no H-bond donor capability, but 1 sits right in 
the middle of 2 and 3 in terms of is lytic ability against both E. coli and S. aureus. 
Presumably, this is due, in-part at least, to its capacity to H-bond both to itself and aggregate 
at the membrane surface, thus disrupting the membranes’ electrical balance, and subsequently 
inducing leakage of cytoplasmic material leading to cell rupture, whereas 4 is unable to do so. 
 
Membrane permeabilisation 
To confirm that the compounds are acting through a membrane disruptive mechanism, as a 
consequence of membrane insertion, rather than through endocytosis, a membrane 
permeabilisation assay was conducted using 1-N-phenylnaphthylamine (NPN) as the 
fluorometric probe.33 NPN fluoresces strongly in phospholipid environments but only weakly 
in aqueous environments, and intact outer membranes of bacteria are able to exclude this 
external hydrophobic probe, forcing it to remain in the aqueous environment. However, in the 
presence of certain membrane-permeabilising agents, the membrane becomes compromised 
and thus sensitive to external factors. As a consequence, this sensitisation allows entry of the 
hydrophobic probe into the hydrophobic environment of the membrane. Thus, by virtue of its 
fluorescence in hydrophobic environments, measuring NPN uptake gives an indication of any 
changes to the permeability of the outer membrane. 
 
Table 4: Percentage uptake of NPN by S. aureus and E. coli in the presence of the test compounds at 2 mM.  
Time Bacteria 1 2 3 4 5 6 7 
1hr 
S. aureus 46.01±5.57 38.91±3.20 69.56±7.31 43.82±5.79 46.26±4.81 40.60±5.49 50.59±1.31 
E. coli 45.29±4.49 33.93±3.21 47.09±3.95 40.75±1.88 40.18±2.83 42.47±5.51 49.57±1.55 
Overnight 
S. aureus 49.40±4.82 19.29±5.60 69.56±9.02 44.34±3.02 53.57±7.47 36.81±5.03 57.33±5.05 
E. coli 30.02±7.76 16.34±4.30 50.93±4.70 38.67±5.20 48.79±11.32 52.87±9.19 52.34±5.39  
 
For the purposes of proof-of-concept, the membrane-permeabilising NPN assay was 
performed at the MIC concentration (2mM), since this is the concentration at which the dose-
dependent curves begin to plateau and would represent the maximum levels of insertion. 
Table 4 shows the percent lysis compared to polymyxin B, an established membrane-
permeable antibacterial peptide, as control.34 Although uptake of NPN into the membrane is 
moderate in the presence of the test compounds (up to 70%, Table 4), compared to 
polymyxin B as control, the MIC activity is overall weak. Nevertheless, the fact that 
membrane insertion is confirmed suggests that potential exists to optimise the lytic properties 
of this compound class, especially if oligomeric constructs can be developed to increase the 
effective concentration of the amphiphilic monomers exposed to the membrane. 
 
Integy moment 
The change in shape associated with N,N’-dimethylation of diarylureas (Figure 1) causes 
aromatic stacking to occur such that the net molecular dimensions are reduced and thus the 
distance between the centre of the lipophilic aromatic sections and the hydrophilic charge is 
reduced in the cis,cis-diarylureas compared to the trans,trans. As a result, the more folded 
cis,cis-conformers would have different integy moments (the integy moment is a measure of 
amphiphilicity which expresses the unbalance between the centre of mass of a molecule and 
the barycenter of its hydrophilic or hydrophobic regions)35 compared to the extended 
trans,trans-conformers, thereby providing a physical property for which to correlate against 
any observed membrane lysis. Unfortunately, attempts to correlate the levels of lysis of S. 
aureus and E. coli membranes with the integy moments (IW) of the test compounds, did not 
yield any noticeable trends, despite precedent of such a correlation being known with 
synthetic peptide mimics,8 suggesting that the lysis activity observed is not due to charge, 
conformation or amphiphilicity in isolation, but that surface aggregation, H-bonding and 
other factors may also play a part. Although in isolation the change in conformation must 
affect the integy moment of compounds 1-3 vs. 4-7, presumably the removal of two 
hydrogen-bond donors (N-H) upon N-methylation to give series 4-7, changes the integy 
moments and complicates any correlation, as does the difference in protonation states of the 
nitrogen atoms under the physiologically relevant pH of 7.4 used. 
 
Conclusion 
We have shown that by varying the molecular charge, shape, and thus amphiphilicity, of a 
series of diarylureas, it is possible to control the level of lysis of membranes composed of 
bacterial lipid extracts. The molecular structures have not been optimised and thus future 
work will set out to combine the best features required for membrane lysis (high pKa 
amine(s) or permanent positive charge(s) and lipophilic group(s), sufficiently separated along 
the molecular axis giving rise to significant integy moments) into new compounds and begin 
to extend the structures to oligomeric scaffolds in the hope of designing new antibacterial 
agents. From the data obtained so far, it appears as though the lysis activity observed is not 
due to charge or amphiphilicity in isolation, but that surface aggregation, H-bonding and 
other factors may also be at play, nevertheless, that membrane permeability takes place has 
been proven in the NPN assay. 
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